Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amylyx Pharmaceuticals

Lots of drug companies talk about putting patients first — but this one actually did

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

WEKU

Amylyx Pharmaceuticals Withdraws ALS Drug Relyvrio From Market

Amylyx Pharmaceuticals withdraws Relyvrio drug for ALS due to lack of efficacy, leading to layoffs and disappointment in ALS community.

Top News

Markets Today: Signs of Progress in Debt Ceiling Talks Boost Stocks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.12%. U.S. stock index futures this morning are moderately higher. Signs of progress on a deal to raise the debt ceiling are lifting stock index futures...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Amylyx Unexpectedly Hits Breakeven With Breakneck Speed — But Shares Dip

Amylyx Pharmaceuticals hit breakeven in its second quarter with a product on the market, an analyst noted Friday. But AMLX stock dipped.

Investors Business Daily

Ice Bucket Challenge Beneficiary Throws Cold Water On Investors

Amylyx Pharmaceuticals announces a not-so-surprising public offering of common stock.

The Street

Highly Rated Amylyx Pharma Skids After Hard-Fought FDA Approval For ALS Drug

The Food and Drug Administration granted Amylyx Pharmaceuticals a hard-won approval in ALS treatment, but AMLX stock sank Friday.

Investors Business Daily

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98

A Relative Strength Rating upgrade for Amylyx Pharmaceuticals shows improving technical performance.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

FDA Faces a Tough Call - and Again Risks Its Credibility

Another controversial neuroscience drug could soon be approved.

The Street

The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff

The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological treatment, and shares crashed.

Investors Business Daily

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Investors Business Daily

Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again

IPO stock Amylyx Pharmaceuticals jumped Monday as the Food and Drug Administration prepares to review its controversial ALS treatment again.

Investors Business Daily

Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate

The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035 with regard to the treatment of patients with amyotrophic lateral sclerosis (ALS).

Benzinga

Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug

The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed.

Investors Business Daily

Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings For Amylyx Pharmaceuticals

Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:

Tribune News Service

Commentary: FDA shouldn’t approve ALS drug without more data

A panel of the Food and Drug Administration’s expert advisers on Wednesday voted 6 to 4 against approving Amylyx Pharmaceuticals’ treatment for ALS. The FDA now has until June 29 to decide whether to follow the panel’s advice or let the closely watched drug on to the market.

Investors Business Daily

Former IPO Scorcher Amylyx Dives After FDA Panel Strikes Down ALS Drug

Shares of IPO stock Amylyx crumbled Thursday after a split FDA committee voted against its experimental ALS treatment.

Investors Business Daily

Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment

The Food and Drug Administration cast doubt on Amylyx Pharmaceuticals' ALS treatment Monday, leading shares to plummet.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Stocks That Hit 52-Week Lows On Monday

On Monday, 147 stocks hit new 52-week lows.

Investors Business Daily

Amylyx Stock Jumps As FDA Mulls ALS Drug — What To Know Ahead Of FDA Action

IPO stock Amylyx Pharmaceuticals surged Friday ahead of an important Food and Drug Administration meeting to discuss its ALS treatment.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Investor Business Daily

Amylyx Pharmaceuticals

20 stories

GBT

20 stories

Wells Fargo Securities

19 stories

Aduhelm

15 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.